Apollo Hospitals (APOLLOHOSP) Q2 FY27 Profit Jumps 33% as Occupancy and Speciality Care Drive Growth
Apollo Hospitals posted a 33.5% surge in Q2 FY27 net profit, driven by higher patient volumes, a richer case mix, and robust growth across its hospital, pharmacy, and diagnostics businesses.
Apollo Hospitals reported a 33.5% jump in net profit for Q2 FY27, with revenue rising 20.8%. Growth was powered by a 14% increase in inpatient volumes, higher occupancy, and strong performance in complex specialties like oncology and cardiology.
For Apollo Hospitals, growth is no longer just about adding beds. The quarter ended September 2026 shows a healthcare giant hitting its stride, where rising occupancy and a deliberate shift toward higher-value treatments are delivering profits faster than revenue.
The numbers tell a clear story of operating leverage. Revenue climbed 20.8% year-on-year to ₹7,614.9 crore, while net profit surged 33.5% to ₹659.5 crore. The net profit margin expanded 90 basis points to 8.7%, a level it held steady from the previous quarter.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 6,303.5
Revenue (₹ Cr), Q3 FY26: 6,477.4
Revenue (₹ Cr), Q4 FY26: 6,605.5
Revenue (₹ Cr), Q1 FY27: 7,043.5
Revenue (₹ Cr), Q2 FY27: 7,614.9
Profit (₹ Cr), Q2 FY26: 494.0
Profit (₹ Cr), Q3 FY26: 516.3
Profit (₹ Cr), Q4 FY26: 551.3
Profit (₹ Cr), Q1 FY27: 610.4
Profit (₹ Cr), Q2 FY27: 659.5
Revenue (₹ Cr)
Revenue (₹ Cr), Q2 FY26: 6,303.5
Revenue (₹ Cr), Q3 FY26: 6,477.4
Revenue (₹ Cr), Q4 FY26: 6,605.5
Revenue (₹ Cr), Q1 FY27: 7,043.5
Revenue (₹ Cr), Q2 FY27: 7,614.9
Profit (₹ Cr)
Profit (₹ Cr), Q2 FY26: 494.0
Profit (₹ Cr), Q3 FY26: 516.3
Profit (₹ Cr), Q4 FY26: 551.3
Profit (₹ Cr), Q1 FY27: 610.4
Profit (₹ Cr), Q2 FY27: 659.5
Net Profit Margin (%)
Net Profit Margin (%), Q2 FY26: 7.8
Net Profit Margin (%), Q3 FY26: 8.0
Net Profit Margin (%), Q4 FY26: 8.3
Net Profit Margin (%), Q1 FY27: 8.7
Net Profit Margin (%), Q2 FY27: 8.7
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Same quarter LYQ2 FY26
Revenue (₹ Cr)
7,614.9YoY +21%
7,043.5
6,303.5
Profit (₹ Cr)
659.5YoY +34%
610.4
494.0
Net Profit Margin (%)
8.7YoY +12%
8.7
7.8
The Volume and Mix Advantage
Growth was broad-based, but the hospital division was the core engine. According to Business Standard, Healthcare Services revenue grew 23% to ₹3,900 crore. This was driven by a 14% jump in inpatient volumes and an 8% rise in average revenue per patient, as reported by CNBC-TV18.
Occupancy improved to 73% from 69% a year ago. More importantly, the case mix tilted toward complex, high-margin specialties. Management told The Hindu BusinessLine that oncology revenue grew 28%, gastroenterology 27%, and urology 26%. International patient services, a high-value segment, saw revenue jump 37%.
Beyond the Hospital Walls
The pharmacy and digital ecosystem provided complementary thrust. Apollo HealthCo, housing the pharmacy and Apollo 24/7 platform, saw revenue rise 23% to ₹3,286 crore, per Financial Express. The digital platform has reached breakeven, and the combined entity is on track for a listing by Q4 FY27.
Live Chart
· APOLLOHOSP
(BSE)
ISIN: INE437A01024
This operational strength allowed profit to outpace revenue despite a 13.9% YoY increase in employee costs. The gains came from operating leverage—spreading fixed costs over more patients—and the richer specialty mix. The quarter's performance also beat analyst estimates, with Zee Business noting revenue and profit came in ahead of its forecasts.
The Expansion Drag and the Regulatory Overhang
The path ahead is not without its speed bumps. The company is in the middle of a massive expansion, planning to add about 5,800 beds over five years. New hospitals, including a 470-bed facility in Gurugram set to open this quarter, currently weigh on margins.
Financial Express reported that newer hospitals generated ₹135 crore in revenue but an EBITDA loss of ₹35 crore in Q2. This drag is expected and guided, but its management is key. A larger, persistent risk is regulatory. Recent Supreme Court observations on drug pricing and a parliamentary panel's recommendations on capping hospital tariffs have cast a shadow over the sector's pricing power.
Key Points
Net profit grew 33.5% YoY, significantly outpacing 20.8% revenue growth, reflecting strong operating leverage and a favorable case mix.
Growth was driven by a 14% increase in inpatient volumes, higher occupancy at 73%, and robust performance in high-margin specialties like oncology and cardiology.
The pharmacy and digital health arm, Apollo HealthCo, reported 23% revenue growth and is on track for a separate listing by Q4 FY27.
Future earnings will balance strong underlying demand against margin pressure from new hospital expansions and potential regulatory headwinds on pricing.
“
Hexa Perspective
Apollo’s quarter confirms the strength of its integrated model when execution aligns. The 90-basis-point annual margin expansion, sustained sequentially, shows core profitability is intact. The story for the next few quarters, however, splits in two.
One thread is the predictable, guided drag from new capacity, which the market has largely priced in. The other is the less quantifiable but significant risk of regulatory intervention on pricing, which could compress the very specialty margins that drove this quarter's outperformance. Investors are buying a proven growth engine, but must watch for any shift in the regulatory tone as closely as they track occupancy rates.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Apollo Hospitals' Q2 FY27 results?
For the quarter ended September 2026 (Q2 FY27), Apollo Hospitals reported a consolidated revenue of ₹7,614.9 crore, a year-on-year growth of 20.8%. Net profit surged 33.5% to ₹659.5 crore. The net profit margin expanded to 8.7% from 7.8% in the same quarter last year.
Why did Apollo Hospitals' profit jump 33% in Q2 FY27?
Apollo Hospitals' profit jumped 33.5% primarily due to strong volume growth and a richer case mix. Inpatient volumes grew 14%, occupancy improved to 73%, and high-margin specialties like oncology and cardiology saw revenue growth of 20-28%, as reported by CNBC-TV18 and Business Standard.
What was Apollo Hospitals' net profit margin in Q2 FY27?
Apollo Hospitals' net profit margin was 8.7% for Q2 FY27. This represents an expansion of 90 basis points compared to the 7.8% margin in Q2 FY26, driven by operating leverage and a favorable shift toward complex, high-value treatments.
How did Apollo Hospitals' pharmacy business perform in Q2 FY27?
The pharmacy and digital health arm, Apollo HealthCo, performed strongly in Q2 FY27. According to Financial Express, its revenue grew 23% year-on-year to ₹3,286 crore. The company added 222 net new stores, taking the total pharmacy network to 7,662 stores.
What is Apollo Hospitals' bed expansion plan?
Apollo Hospitals plans to add around 5,800 beds over the next five years. A new 470-bed facility in Gurugram is on track for commissioning in Q3 FY27. This expansion is part of a larger strategy to increase capacity, though new hospitals typically incur initial losses during the ramp-up phase.
Did Apollo Hospitals' Q2 FY27 results beat estimates?
Yes, Apollo Hospitals' Q2 FY27 results beat analyst estimates. According to Zee Business, the company's reported revenue of ₹7,615 crore and net profit of ₹630 crore were higher than their estimates of ₹7,481 crore and ₹629 crore, respectively.
What is the outlook for Apollo Hospitals after Q2 FY27?
The outlook remains positive on volume growth but cautious on margins. Management will focus on ramping up newly commissioned hospitals while navigating potential regulatory risks. The company maintains its guidance, with the Apollo HealthCo business slated for a potential listing by Q4 FY27.
What are the regulatory risks for Apollo Hospitals?
Key regulatory risks include potential price caps on medical procedures, hospital room tariffs, and medicines. Recent Supreme Court observations on high drug mark-ups and parliamentary committee recommendations have increased scrutiny, which could impact future pricing power and profitability.
Apollo Hospitals Q2 net profit rises 32% to ₹630 crore; revenue up 23%
For Q2 FY27, Apollo Hospitals reported a net profit of ₹659.5 crore, a 33.5% increase year-on-year. Consolidated revenue was ₹7,614.9 crore, up 20.8%. The figures in some reports, like Business Standard's ₹630 crore profit, may refer to adjusted numbers, but the underlying growth trend is robust.
Apollo Hospitals Q2 results: Profit jumps over 33% to ₹660 crore, revenue rises 23%
Apollo Hospitals' Q2 FY27 results showed a profit of ₹659.5 crore, a 33.5% jump from the year-ago quarter. Revenue rose 20.8% to ₹7,614.9 crore. The performance was driven by higher patient volumes, improved occupancy at 73%, and strong growth in specialty treatments.
Apollo Hospitals Q2 FY27 results order book
As a hospital chain, Apollo Hospitals does not report a traditional 'order book.' Its future visibility comes from its bed occupancy rate, which was 73% in Q2 FY27, and a strong pipeline of patient volumes driven by demand for complex specialties. The company also has a clear expansion plan to add about 5,800 beds over five years.